Summary

Eligibility
for people ages 45-75 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

Official Title

A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease

Keywords

Parkinson Disease, Gene therapy, AAV2-GDNF Gene therapy, AAV2-GDNF

Eligibility

You can join if…

Open to people ages 45-75

Age

  1. Male and female adults 45-75 years of age inclusive, at the time of signing of informed consent Type of Subject and Disease Characteristics
  2. Diagnosed with Parkinson's Disease in the past 4-10 years (inclusive) as defined by the following:
    1. Presence of bradykinesia PLUS any of the following:
      • Rigidity
      • Rest Tremor
      • Postural instability
    2. Presence of motor fluctuations as measured by the PD Motor Diary
    3. Stable anti-parkinsonian medication regiment for >/= 4 weeks prior to screening
    4. Must demonstrate responsiveness to levodopa therapy

You CAN'T join if...

  • Known history or current evidence of medical, genetic, or neurological conditions that may provide an alternative to idiopathic PD diagnosis
  • Presence or history of significant vascular and/or cardiovascular disease
  • Presence of significant cognitive impairment, poorly controlled depression/anxiety
  • Presence or history of psychosis or impulse control disorder
  • History of malignancy other than treated cutaneous squamous or basal cell carcinomas
  • Presence of clinically relevant conditions that could compromise surgical suitability and/or subject safety
  • Contraindication to magnetic resonance imaging and/or use gadolinium-based contrast agents
  • Prior history of brain surgery including, but no limited: DBS, pallidotomy focused ultrasound thalamotomy, or other experimental neurosurgical procedure
  • Chronic immunosuppressive therapy

Locations

  • UCSF (Neurology) not yet accepting patients
    San Francisco California 94143 United States
  • Loma Linda University (Neurology) not yet accepting patients
    Loma Linda California 92354 United States
  • University of Kansas Medical Center (Neurology) accepting new patients
    Kansas City Kansas 66103 United States
  • Houston Methodist (Neurology) accepting new patients
    Houston Texas 77030 United States
  • Houston Methodist (Surgical) in progress, not accepting new patients
    Houston Texas 77030 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Asklepios Biopharmaceutical, Inc.
ID
NCT06285643
Phase
Phase 2 Parkinson's Disease Research Study
Study Type
Interventional
Participants
Expecting 87 study participants
Last Updated